“Your primary endpoint is now down to a subjective measure in different trial centres, perhaps done by different people with different subjectivity,” says David van Zuydam, CEO of Head Therapeutics. “And now we’re going to determine whether this drug is actually performing or not over a certain period of time, using this big subjective system? So you can only imagine things can go wrong in that space.”